4 results match your criteria: "IRCCS Candiolo Cancer Institute-FPO[Affiliation]"
Multiparametric magnetic resonance imaging-targeted prostate biopsy: present and future of the prostate cancer diagnostic pathway.
Minerva Urol Nephrol
February 2021
Department of Radiology, IRCCS Candiolo Cancer Institute - FPO, Candiolo, Turin, Italy.
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Int J Nanomedicine
March 2019
Department of Internal Medicine, Pneumology Unit, University of Pavia, Pavia, Italy.
Purpose: Malignant pleural mesothelioma (MPM) is an aggressive tumor characterized by poor prognosis. Its incidence is steadily increasing due to widespread asbestos exposure. There is still no effective therapy for MPM.
View Article and Find Full Text PDFErratum to: Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer.
J Transl Med
September 2017
Experimental Clinical Molecular Oncology (ECMO), IRCCS Candiolo Cancer Institute-FPO, Candiolo, 20060, Turin, Italy.
In the original version of this article [1], published on 2 September 2016, the name of author 'Alice Balderacchi' was wrongly displayed. In this Erratum the incorrect name and correct name are shown. The original publication of this article has been corrected.
View Article and Find Full Text PDFOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer.
J Transl Med
September 2016
Experimental Clinical Molecular Oncology (ECMO), IRCCS Candiolo Cancer Institute-FPO, Candiolo, 20060, Turin, Italy.
Background: Idiopathic pulmonary fibrosis (IPF) identifies a specific lung disorder characterized by chronic, progressive fibrosing interstitial pneumonia of unknown etiology, which lacks effective treatment. According to the current pathogenic perspective, the aberrant proliferative events in IPF resemble those occurring during malignant transformation.
Main Body: Receptor tyrosine kinases (RTK) are known to be key players in cancer onset and progression.